CryoCell International Inc (CCEL)vsDaVita HealthCare Partners Inc (DVA)
CCEL
CryoCell International Inc
$3.42
-3.36%
HEALTHCARE · Cap: $23.36M
DVA
DaVita HealthCare Partners Inc
$232.80
+1.45%
HEALTHCARE · Cap: $15.13B
Smart Verdict
WallStSmart Research — data-driven comparison
DaVita HealthCare Partners Inc generates 44129% more annual revenue ($13.84B vs $31.28M). DVA leads profitability with a 5.7% profit margin vs -8.5%. DVA appears more attractively valued with a PEG of 0.73. DVA earns a higher WallStSmart Score of 67/100 (B-).
CCEL
Hold39
out of 100
Grade: F
DVA
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+34.8%
Fair Value
$5.12
Current Price
$3.42
$1.70 discount
Margin of Safety
-16.4%
Fair Value
$123.91
Current Price
$232.80
$108.89 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 129 in profit
Conservative balance sheet, low leverage
Every $100 of equity generates 81 in profit
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 43.5% YoY
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 3.6%
Earnings declined 80.5%
Distress zone — elevated risk
5.7% margin — thin
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CCEL
The strongest argument for CCEL centers on Return on Equity, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bull Case : DVA
The strongest argument for DVA centers on Return on Equity, Debt/Equity, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.
Bear Case : CCEL
The primary concerns for CCEL are Market Cap, Revenue Growth, EPS Growth.
Bear Case : DVA
The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.
Key Dynamics to Monitor
CCEL profiles as a turnaround stock while DVA is a value play — different risk/reward profiles.
DVA carries more volatility with a beta of 0.88 — expect wider price swings.
DVA is growing revenue faster at 6.0% — sustainability is the question.
DVA generates stronger free cash flow (219M), providing more financial flexibility.
Bottom Line
DVA scores higher overall (67/100 vs 39/100). CCEL offers better value entry with a 34.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CryoCell International Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.
DaVita HealthCare Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?